301 related articles for article (PubMed ID: 32862332)
1. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
2. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma.
He J; Makey D; Fojo T; Adams KT; Havekes B; Eisenhofer G; Sullivan P; Lai EW; Pacak K
Endocrine; 2009 Oct; 36(2):189-93. PubMed ID: 19618298
[TBL] [Abstract][Full Text] [Related]
3. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
5. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
6. Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.
Makis W; McCann K; McEwan AJ; Sawyer MB
Clin Nucl Med; 2016 Mar; 41(3):204-6. PubMed ID: 26359568
[TBL] [Abstract][Full Text] [Related]
7. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
8. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma.
Moraitis AG; Martucci VL; Pacak K
Endocr Pract; 2014 Feb; 20(2):176-87. PubMed ID: 24449662
[TBL] [Abstract][Full Text] [Related]
9. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
Jasim S; Jimenez C
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101354. PubMed ID: 31685417
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
11. Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM; Snel M; Kapiteijn E
Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
[TBL] [Abstract][Full Text] [Related]
12. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
13. [Pediatric pheochromocytoma and paraganglioma: an update].
Garnier S; Réguerre Y; Orbach D; Brugières L; Kalfa N
Bull Cancer; 2014 Oct; 101(10):966-75. PubMed ID: 25373696
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
15. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
[TBL] [Abstract][Full Text] [Related]
16. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
17. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and management of metastatic pheochromocytoma and paraganglioma].
Jochmanová I; Lazúrová I
Vnitr Lek; 2017; 63(9):580-588. PubMed ID: 29120654
[TBL] [Abstract][Full Text] [Related]
20. [Pheochromocytoma and paraganglioma: basics for the general practitioner].
Loosli N; Köhler BB; Pechère-Bertschi A; Karenovics W; Triponex F
Rev Med Suisse; 2014 Sep; 10(441):1650-2, 1654-5. PubMed ID: 25322623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]